29.2.12 Cytonet Recognizes Rare Disease Day with Efforts to Help Ensure – UCD Diagnoses Are Not Missed
Heidelberg/Germany, February 27, 2012 – For parents of babies born with urea cycle disorders (UCD), the joy of giving birth to a perfect baby can quickly turn to devastation as the baby’s health rapidly declines, going from symptoms such as being tired and irritable, to not eating, to experiencing seizures and coma. UCDs are congenital and often life-threatening disorders of ammonia metabolism in the liver that cause neurotoxic ammonia to accumulate in the body, potentially leading to massive damage of the nerves and the brain and death. Read on...
14.2.12 Cytonet Trials Aim to Better Assess Severity of Urea Cycle Disorders – Using New Assay for Urea Production
Heidelberg/Germany, February 2012 – International biotechnology firm Cytonet has launched a new clinical trial in Germany to compare the urea cycle activity of pediatric patients suffering from urea cycle disorders (UCD) to normal healthy children using an innovative assay to measure urea production. Researchers hope to provide a diagnostic tool to predict the severity of the urea cycle defect. Read on...
6.12.11 CYTONET SPONORS RIDER ON DONATE LIFE ROSE PARADE FLOAT
Fort Worth/ Texas, November 2011 – Giant floral clocks will rise above 28 individuals whose participation as riders aboard Donate Life’s ninth Rose Parade Float will inspire others to save and heal lives through the gifts of organ, eye and tissue donation. Through their life-changing experiences, the families of organ and tissue donors, living donors and recipients know intimately the preciousness of time. On Jan. 2, 2012 their presence will help bring special meaning to the float’s theme, “One More Day.” Read on...
6.12.11 American SELICA III trial to be extended into Canada
Weinheim/ Germany, October 2011 –The Canadian health authority, Health Canada, recently granted Cytonet approval to extend the SELICA III trial, which has been open in the United States since 2010, into Canada.
The clinical trial is designed to evaluate the safety and efficacy of liver cell therapy in infants to children up to age 5 with urea cycle disorders (UCD). Two centers in Canada join the 12 medical centers in the United States taking part in the trial: the Alberta Children’s Hospital in Calgary and the Hospital for Sick Kids in Toronto. Read on...
4.7.11 ‘Top 100’ recognises the country’s most innovative companies. This year, Cytonet GmbH & Co. KG is among them
Weinheim, Germany, 1st July 2011 – Dedicated employees, creative inquiry and above all the courage to dare to venture into largely ‘undeveloped ground’ of medicine have brought this medium-sized enterprise to the top – to a position on the list of Germany’s 100 top innovators. On Thursday evening, in Rostock Warnemünde, Lothar Späth presented Cytonet, the medical-biotechnological company with the ‘Top 100’ seal of quality. Read on...
24.5.11 CYTONET’S LIVER CELL THERAPY AWARDED ORPHAN DRUG DESIGNATION
Weinheim, Germany, May 17, 2011 – International biotechnology firm Cytonet, which is investigating a liver cell infusion of donated human liver cells for the treatment of urea cycle disorders (UCD) in young children, announced it has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA).
“This designation recognizes our work to advance the landscape of UCD treatment for young children and offer a much-needed new option for a very serious condition where the only current cure is liver transplantation,” says Dr. Wolfgang Rüdinger, CEO and CSO of Cytonet Germany. “Orphan drug designation enhances our ability to execute the SELICA III trials on this novel treatment.” Read on...
13.4.11 LIVER CELL INFUSION PERFORMED FOR FIRST TIME IN THE UNITED STATES
Cytonet Launches Phase II Trial for Hereditary Urea Cycle Disorders (UCD) in Children
Weinheim, Germany, April 2011 – International biotechnology firm Cytonet recently launched the first ever clinical trial in the United States using an investigational liver cell infusion to treat urea cycle disorders (UCD) in children. The first patient in the Phase II trial, which will seek to enroll 20 patients in 12 medical centers, is a child with citrullinemia, which is a hereditary UCD. He received six liver cell infusions on six consecutive days at Yale School of Medicine in New Haven, Conn. Read on...
16.2.11 Q&A Session
Liver Cell Therapy in Children with Urea Cycle Defect
Experience of Liver Cell Treatment of 1st Child Treated in the US and 7 children treated in Germany
Dr. Sukru Emre
Yale –New Haven Transplantation Center
Chief of Organ Transplantation
ASTS Winter Symposium, Hollywood
Date: Friday, January 14th, 1 pm to 4 pm
Location: Exhibitor HallCytonet, Booth No 306/308
27.10.10 Joint Venture between Weinheim Biotech Company Cytonet and Hamad Medical Corporation in Qatar to promote Liver Cell Therapy
Doha / Qatar 11 October 2010 – The German biotech company Cytonet GmbH & Co. KG in Weinheim, the University Children’s Hospital in Heidelberg and the Hamad Medical Corporation (HMC) medical centre in Doha, Qatar have signed a partnership agreement: a joint venture between the Weinheim specialist for regenerative medicine and the two renowned clinics was sealed on 11 October 2010 during the Newborn-Screening-Congress in Doha, Qatar. This close cooperation should enable affected children who suffer from urea cycle defects to be quickly included in the German liver cell therapy study programme that is being developed by Cytonet. This future treatment option for urea cycle defects – severe and life-threatening metabolic disorders of the liver – is currently undergoing clinical examination. Within the framework of this cooperation agreement, physicians are also to be given further training as they work together with the metabolic experts at Heidelberg University Hospital. Leading investigator is Prof. Dr. Georg Hoffmann, Head of the University Children’s Hospital in Heidelberg, who is a long-standing cooperation partner of Cytonet. Read on...